Simcere Pharmaceutical’s Quviviq Secures Hong Kong Marketing Approval for Insomnia Treatment
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received marketing approval...
HKG: 2096
Simcere Pharmaceutical’s SIM0500 Earns FDA Fast-Track Designation for Multiple Myeloma
Simcere Pharmaceutical Group (HKG: 2096), a leading China-based pharmaceutical company, has announced that its trispecific...
Simcere Pharmaceutical Reports 4.5% Revenue Growth in 2023 Amid Shifts in Profitability
Simcere Pharmaceutical Group (HKG: 2096), based in China, has released its 2023 financial performance report,...
Simcere Pharmaceutical’s Suvemcitug Files for Approval in China for Recurrent Ovarian Cancer
Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that an...
Simcere Pharmaceutical Gets NMPA Approval for Clinical Study of Trispecific Antibody SIM0500
Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that it...
Simcere Secures FDA Approval for Clinical Study of Trispecific Antibody SIM0500 in Multiple Myeloma
Simcere Pharmaceutical Group (HKG: 2096), based in China, has received approval from the U.S. Food...
Simcere Pharmaceutical’s Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development
Simcere Pharmaceutical Group (HKG: 2096) has announced that its oncology subsidiary, Simcere Zaiming Pharmaceutical Co.,...
Alphamab and 3D Medicines License Envafolimab Rights to Glenmark for Multiple Regions
Alphamab Oncology (HKG: 9966) and 3D Medicines (HKG: 1244), two Chinese pharmaceutical companies, have announced...
Simcere Pharmaceutical Group Gets NMPA Green Light for USP1 Inhibitor SIM0501
Simcere Pharmaceutical Group (HKG: 2096) has announced that it has received clinical trial approval from...
Simcere Secures Approval for Local Manufacturing of Cosela, Boosting Patient Access
China-based Simcere Pharmaceutical Group (HKG: 2096) has received supplementary filing approval for its drug Cosela...
Lynk Pharmaceuticals Initiates Phase III Clinical Trial for Rheumatoid Arthritis Drug in China
China-based Lynk Pharmaceuticals Co., Ltd has announced that the first patient has been dosed in...
Simcere Pharmaceutical’s SIM0501 Receives FDA Approval for Advanced Solid Tumor Clinical Trial
Simcere Pharmaceutical Group (HKG: 2096) has announced that it has received clinical trial approval from...
Simcere Secures NMPA Approval for Edaravone Sublingual Tablets Targeting Post-Stroke Cognitive Impairment
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has received clinical trial approval from the National...
Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China
China’s Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into an agreement to acquire the...
Simcere Pharmaceutical Group Secures Full Approval for Cosela in China
Simcere Pharmaceutical Group (HKG: 2096), a leading pharmaceutical company based in China, has announced that...
Alphamab Oncology and 3D Medicines Gain FDA Approval for Envafolimab Phase III Trial
Partners Alphamab Oncology (HKG: 9966) and 3D Medicines (HKG: 1244) have announced that they have...
Simcere’s SIM0237 Receives NMPA Approval for Bladder Cancer Trial
China-based pharmaceutical innovator Simcere Pharmaceutical Group (HKG: 2096) has announced the receipt of an additional...
Simcere Pharmaceutical Secures Exclusive Rights to AnDiCon’s Anti-Influenza Candidate ADC189
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced a strategic collaboration agreement with domestic firm...
Hong Kong Government Partners with AstraZeneca, Tigermed, and Simcere to Boost Innovation
The government of the Hong Kong Special Administrative Region has entered into significant partnership agreements...
Simcere Pharmaceutical Group Secures Exclusive Rights to CMAB009 in China
Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced that its subsidiary, Jiangsu Simcere Zaiming Pharmaceutical...